Intermittent Claudication - Drug therapy
Research News and Information

Sunday, November 22, 2009

Selective cyclooxygenase-2 inhibition reduces endothelial dysfunction and improves inflammatory status in patients with intermittent claudication.

30 Jul 2009 INTRODUCTION AND OBJECTIVES: Both endothelial dysfunction and a proinflammatory state are present during the early stages of atherosclerosis. In this context, increased expression of cyclooxygenase-2 (COX-2) results in higher levels of ... Read more...

Clinical and microcirculatory effects of transcutaneous CO2 therapy in intermittent claudication. Randomized double-blind clinical trial with a parallel design.

30 Jul 2009 BACKGROUND: This randomized, double blind trial determined the short and long-term clinical and hemodynamic vasodilator effects induced by percutaneous applications of natural CO2 gas in patients with moderate Fontaine stage II. PATIENTS AND ... Read more...

Bilateral asymmetric popliteal entrapment syndrome treated with successful surgical decompression and adjunctive thrombolysis.

21 Jul 2009 Popliteal artery entrapment syndrome (PAES) is the most common cause of lower leg claudication in patients younger than 50 years. The different types of PAES can result in different rates of arterial damage, leading to aneurysmal degeneration or ... Read more...

Latest indexed articles for 'Intermittent Claudication - Drug therapy'

These are the very latest articles for this heading:

• Selective cyclooxygenase-2 inhibition reduces endothelial dysfunction and improves inflammatory status in patients with intermittent claudication. 30 Jul 2009
• Clinical and microcirculatory effects of transcutaneous CO2 therapy in intermittent claudication. Randomized double-blind clinical trial with a parallel design. 30 Jul 2009
• Bilateral asymmetric popliteal entrapment syndrome treated with successful surgical decompression and adjunctive thrombolysis. 21 Jul 2009
• Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. 5 Jul 2009
• Current management of intermittent claudication: the role of pharmacological and nonpharmacological symptom-directed therapies. 29 Jun 2009
• The influence of atorvastatin on walking performance in peripheral arterial disease. 29 Apr 2009
• Pharmacologic therapy for intermittent claudication. 29 Apr 2009
• Ginkgo biloba for intermittent claudication. 13 Apr 2009
• Beta blockers for peripheral arterial disease. 7 Apr 2009
• Cilostazol: new drug. Intermittent claudication: too little efficacy, too many risks. 30 Mar 2009
• Selective and sustained delivery of basic fibroblast growth factor (bFGF) for treatment of peripheral arterial disease: results of a phase I trial. 24 Mar 2009
• Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data. 8 Mar 2009
• Risk factor profile, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective German REACH registry cohort. 14 Feb 2009
• Endovascular treatment of an occluded popliteal aneurysm with locoregional thrombolysis followed by stent graft exclusion. 30 Jan 2009
• Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1). 10 Jan 2009
• The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. 6 Jan 2009
• Bias in benefit-risk appraisal in older products: the case of buflomedil for intermittent claudication. 30 Dec 2008
• The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. 25 Dec 2008
• Nurse-led risk assessment/management clinics reduce predicted cardiac morbidity and mortality in claudicants. 29 Nov 2008
• The prostacyclin analogue iloprost increases circulating endothelial progenitor cells in patients with critical limb ischemia. 30 Oct 2008

See a longer list of these articles.

Technical information about 'Intermittent Claudication'

Definition: A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and weakness brought on by walking. Such muscle limpness disappears after a brief rest and is often relates to arterial STENOSIS; muscle ISCHEMIA; and accumulation of LACTATE.

Descriptor UI: D007383

Alternative terms: Intermittent Claudication; Claudication, Intermittent;

Allowable Qualifiers: blood; cerebrospinal fluid; chemically induced; classification; complications; congenital; diagnosis; diet therapy; drug therapy; economics; embryology; enzymology; ethnology; etiology; genetics; history; immunology; metabolism; microbiology; mortality; nursing; epidemiology; parasitology; pathology; physiopathology; prevention & control; psychology; radiography; radionuclide imaging; radiotherapy; rehabilitation; surgery; therapy; urine; veterinary; ultrasonography; virology;

Tree Number: C14.907.137.126.669; C23.888.531;